- Home
- EXFY vs OLMA Comparison
EXFY vs OLMA Comparison
Compare EXFY & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- OLMA
- Stock Information
- Founded
- EXFY 2008
- OLMA 2006
- Country
- EXFY United States
- OLMA United States
- Employees
- EXFY N/A
- OLMA N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- OLMA Health Care
- Exchange
- EXFY Nasdaq
- OLMA Nasdaq
- Market Cap
- EXFY 253.2M
- OLMA 289.0M
- IPO Year
- EXFY 2021
- OLMA 2020
- Fundamental
- Price
- EXFY $2.30
- OLMA $4.05
- Analyst Decision
- EXFY Buy
- OLMA Strong Buy
- Analyst Count
- EXFY 4
- OLMA 4
- Target Price
- EXFY $4.75
- OLMA $24.50
- AVG Volume (30 Days)
- EXFY 482.5K
- OLMA 673.0K
- Earning Date
- EXFY 05-08-2025
- OLMA 05-13-2025
- Dividend Yield
- EXFY N/A
- OLMA N/A
- EPS Growth
- EXFY N/A
- OLMA N/A
- EPS
- EXFY N/A
- OLMA N/A
- Revenue
- EXFY $141,775,000.00
- OLMA N/A
- Revenue This Year
- EXFY $7.77
- OLMA N/A
- Revenue Next Year
- EXFY $5.45
- OLMA N/A
- P/E Ratio
- EXFY N/A
- OLMA N/A
- Revenue Growth
- EXFY N/A
- OLMA N/A
- 52 Week Low
- EXFY $1.24
- OLMA $2.86
- 52 Week High
- EXFY $4.13
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- EXFY 41.46
- OLMA 37.13
- Support Level
- EXFY $2.16
- OLMA $4.80
- Resistance Level
- EXFY $2.50
- OLMA $5.61
- Average True Range (ATR)
- EXFY 0.11
- OLMA 0.44
- MACD
- EXFY 0.00
- OLMA -0.09
- Stochastic Oscillator
- EXFY 42.03
- OLMA 2.19
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.